Asset Purchase and Merger Agreements (Narrative) (Details) - USD ($) $ in Thousands |
3 Months Ended | 27 Months Ended | |||
|---|---|---|---|---|---|
Jul. 15, 2024 |
Mar. 31, 2025 |
Mar. 31, 2024 |
Mar. 31, 2025 |
Dec. 31, 2024 |
|
| Outstanding receivables | $ 18,025 | $ 18,025 | $ 10,231 | ||
| Outstanding payables | 27,818 | 27,818 | $ 31,636 | ||
| Crystalys Therapeutics, Inc | |||||
| Capitalization in equity securities | $ 150,000 | ||||
| Avenue | InvaGen | |||||
| Contingent fee payable from proceeds of future financing | 4,000 | 4,000 | |||
| Payments of milestones | $ 200 | $ 300 | $ 1,400 | ||
| Percentage of contingent fee payable | 7.50% | 7.50% | |||
| Urica | |||||
| Percentage of equity to be held | 35.00% | ||||
| Urica | Crystalys Therapeutics, Inc | |||||
| Percentage of royalty on future net sales | 3.00% | ||||
| Urica's equity position | 15.00% | ||||
| Maximum repurchase amount of assets sold under agreements | $ 6,400 | ||||
| Amount of minimum qualified financing required | 120,000 | ||||
| Liability | $ 600 | ||||
| Recorded accretion | $ 700 | $ 700 | |||
| X | ||||||||||
- Definition Percentage of common stock issued to the company, pursuant to asset acquisition arrangement. No definition available.
|
| X | ||||||||||
- Definition Amount of accretion expense recognized under assets sold under repurchase agreements for the passage of time, typically for liabilities, that have been discounted to their net present values. No definition available.
|
| X | ||||||||||
- Definition Maximum repurchase amount of assets sold under agreements to repurchase when the carrying amount (or market value, if higher than the carrying amount) of securities or other assets sold under repurchase agreements exceeds 10 percent of total assets. No definition available.
|
| X | ||||||||||
- Definition Represents maximum amount of equity securities to be raised by the company. No definition available.
|
| X | ||||||||||
- Definition It represents payments of milestone. No definition available.
|
| X | ||||||||||
- Definition Percentage of royalty on future net sales granted to the company. No definition available.
|
| X | ||||||||||
- Definition Amount of contingent fee payable on the proceeds of future financings. No definition available.
|
| X | ||||||||||
- Definition Percentage of contingent fee payable on the proceeds of future financings. No definition available.
|
| X | ||||||||||
- Definition Threshold percentage of fully diluted equity capitalization position in counterparty, to be held by company, until specified amount of equity securities is raised by such counterparty. No definition available.
|
| X | ||||||||||
- Definition The amount of minimum qualified financing required for the expiry of repurchase option No definition available.
|
| X | ||||||||||
- Definition Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|